Category: Uncategorized

Recognized as one of Europe’s Leading Drug Delivery and Manufacturing Companies by Euro Insights Care, Curapath continues to set benchmarks in the field of advanced non-viral drug delivery systems. This accolade underscores the company’s pivotal role in shaping innovative solutions, particularly in polymer and lipid-based therapies. Curapath specializes in the

VALENCIA & ZARAGOZA, SPAIN, 07 OCT 2024. Curapath, a leading innovator in the manufacturing of novel lipid and polymer excipients, nanoparticle formulations and innovative polymer conjugates, and Certest Biotech, a Spanish company focused on the development of new products with special emphasis in Drug Delivery with Lipid Nanoparticles (LNPs) and Active Pharmaceutical

BOSTON and VALENCIA, Feb. 14, 2024 – Curapath, a leader in the development and custom manufacturing of polymer- and lipid-based delivery systems for advanced therapies, has entered into a multiyear Development and Manufacturing Services Agreement with a key customer located in North America. Under this agreement, Curapath will leverage its

Curapath, a developer, manufacturer, and formulator of lipid- and polymer-based nanoparticles used in advanced therapeutic delivery technology, today announced the appointment of Philippe Clavel as Chief Executive Officer. Curapath is a portfolio company of Arcline Investment Management. Philippe has previously held leadership positions in the pharmaceutical and biotechnology industries. Most recently, he

Valencia, Spain and Boston, MA, January 26, 2023 – Curapath, a leader in the design, development, andcustom manufacturing of polyamino-acid- and lipid nanoparticle (LNP) delivery systems for therapeuticsand vaccines, today announced the company has received accreditation as a GMP investigational drugproduct manufacturer from the Spanish Agency for Medicine and Health Products

Curapath will develop and optimize a process to produce a nanoparticle formulation for the vaccine Valencia, Spain and Boston, MA, November 16, 2022 – Curapath, a leader in the design, development, and custom manufacturing of polyamino-acid- and lipid-based nanoparticle delivery systems for therapeutics and vaccines, today announced a collaboration with

Expanded capabilities support development and production of novel functional lipid excipients and nanoparticle formulation Addition of late stage clinical and commercial-scale production is also planned Company to present on shielding lipid novel excipients for lipid nanoparticle (LNP) formulations at Lipid Nanoparticles Development Summit on October 20th Valencia, Spain and Boston,

PaternaMajor and the Spanish Government Innovation Delegation identified Curapath (formerly PTS), as one of the most innovative companies in the Valencian Community region. The Government delegate in the Valencian Community, Pilar Bernabe, visited the Paterna Technology Park, an area that has a number of high-tech industries, research centers and significant focus

Curapath, (formerly PTS) a leader in the custom design, development, and end-to-end GMP manufacture of polymer and lipid-based drug delivery systems is partnering with the organizers of the LNP Development Europe Summit. Dr. Vicent Nebot, CTO of Curapath, will be delivering a talk entitled “Development of Shielding Lipid Novel Excipients for